ICM Editors’ reply to a letter by Wiedermann “Institutional recommendation for the withdrawal of scientific articles from Joachim Boldt”

Giuseppe Citerio* on behalf of the ICM Editorial Board

We the Editorial Board of Intensive Care Medicine (ICM) acknowledge receipt of the Letter to the Editor by C. J. Wiedermann [1] concerning the body of work by Joachim Boldt [2]. Wiedermann calls upon ICM to support research integrity by re-evaluating the articles by Boldt that have not been retracted.

Integrity in research requires that authors publish results of an honest, rigorous, transparent and open research process, undertaken with care and respect. Scientific misconduct could have an impact on clinical management at the bedside as has happened in the past with Boldt’s work [3].

Therefore, ICM is considering seriously the question raised about the integrity of science and scientific misconduct [4–6]. Some editorial actions had already been taken in 2011: nine articles were retracted by ICM following a statement by the Editors in Chief of 11 journals, including ICM, regarding Institutional Review Board (IRB) approval of clinical trials undertaken by Boldt. The current Editor-in-Chief acted in 2020 by retracting further articles published in ICM after having them re-reviewed by a panel of specialists. Papers that based their conclusion on subsequently retracted articles were also retracted because this rendered their content unreliable. Priority was given to the relatively recent articles, documented, and liable to impact on clinical decisions and ultimately on patients’ health.

A discussion with the Publisher was started some time ago after the request of colleagues to reconsider all of Boldt’s bibliography. However, retracting a published article is a lengthy process, and Publishers require many steps with all the authors based on detailed allegations, according to guidelines of the Committee on Publication Ethics (COPE). The process is meant to guarantee that the decision to retract is based on evidence.

We followed COPE’s Retraction guidelines [7] but our investigation was inconclusive due to the difficulties in accessing the original documentation of work performed many years ago. By the admission of the investigative board of Klinikum Ludwigshafen in 2011, original data and other information are not available for all articles, thus making it very difficult to ascertain the allegations. The statement by Justus Liebig University dated 14.11.2018 invites Editors to consider retraction of all Boldt’s papers “even if there is no obvious indication of falsification”.

The ICM Editors, after receiving Wiedermann letter, are now working with the Publisher to retract the remaining articles where Boldt is the responsible author and to annotate his other articles with an ‘expression of concern’ note.

Even though evidence of fraud cannot be ascertained, the Editors considered it prudent to proceed and warn readers about the unreliability of Joachim Boldt’s scientific production again.
Acknowledgements
ICM Editorial Board: Giuseppe Citerio, Department of Medicine and Surgery, School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy; Samir Jaber, Department of Anaesthesia and Intensive Care, Montpellier Saint Eloi University Hospital, and PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France; Aoife Abbey, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom; Thomas Bein, Faculty of Medicine, University of Regensburg, Regensburg, Germany; Katherine Brown, Cardiac and Critical Care Division, Great Ormond Street Hospital NHS Foundation Trust, London, UK; Alain Combes, Sorbonne Université INSERM Unité Mixte de Recherche (UMRS) 1166, Institute of Cardiometabolism and Nutrition, Service de Médecine Intensive-Réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris (APHP) Hôpital Pitié-Salpêtrière, Paris, France; Audrey De Jong, Saint Eloi ICU, Montpellier University Hospital, PhyMedExp, INSERM, CNRS, Montpellier, France; Julie Helms, Strasbourg University Hospital, Strasbourg, France; Geert Meyfroidt, Laboratory of Intensive Care Medicine, Academic Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium; Laveina Munshi, Interdepartmental Division of Critical Care Medicine, Sinai Health System/University Health Network, University of Toronto, Toronto, Canada; Marlies Ostermann, Department of Critical Care and Nephrology, King's College London, Guy's and St Thomas' Hospital, London, UK; Pedro Póvoa, NOVA Medical School, CHRC, New University of Lisbon, Campo dos Mártires da Pátria, 130, 1169-056, Lisbon, Portugal / Center for Clinical Epidemiology and Research Unit of Clinical Epidemiology, ODH Odense University Hospital, Odense, Denmark / Polyvalent Intensive Care Unit, Hospital de São Francisco Xavier, CHLO, Lisbon, Portugal; Otavio T. Ranzani, Pulmonary Division, Heart Institute, Universidade de São Paulo, São Paulo, Brazil and Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain; Claudio Sandroni, Istituto Anestesiologia e Rianimazione, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, Rome, Italy; Manu Shankar-Hari, Intensive Care National Audit & Research Centre, London, United Kingdom and Department of Intensive Care, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, United Kingdom and Division of Infection, Immunity and Inflammation, Kings College London, London, United Kingdom.

References

Declarations
Conflicts of interest
None to declare.